Retina

João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases

In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment.

Franklin shares how methotrexate significantly reduces reoperation rates in diabetic patients with retinal detachments, enhancing postoperative outcomes and vision.

In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment

Survey reveals severe impact of Good Days underfunding on retina practices, with many patients experiencing vision loss due to delayed access to care.

GLP-1 therapies could impact long-term outcomes in diabetic retinopathy

An intravitreal implant shows promise in enhancing visual function and retinal structure in diabetic retinopathy patients, according to recent research.

Matthew Starr, MD, discusses techniques for correcting astigmatism in patients lacking capsular support, enhancing visual outcomes surgery.

Enhanced screenings and a unified registry could save vision and lives

Ophthalmology celebrates 50 years of groundbreaking innovations, highlighting anti-VEGF therapies, OCT imaging, and future advancements in eye care.

4D-150 is an investigational agent designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

Steven D. Ness, MD, discusses his research on vitamin D's role in reducing complications after retinal surgery at ASRS 2025.

At ASRS 2025, Andrew G Lee, MD, gave key insight into the world of a neuro-ophthalmologist and why and when a retina specialist should consult a neuro-ophthalmologist

Christina Weng, MD, MBA, FASRS, explores the viability of postoperative day 0 exams as a substitute for day 1 after vitreoretinal surgery, revealing promising findings.

Optomed Lumo launches a versatile handheld fundus camera, enhancing retinal imaging accessibility in diverse healthcare settings across the US.

The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025.

Topcon Healthcare enhances its connected care model by acquiring IRIS, integrating AI for improved diabetic eye disease screening and patient coordination.